deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT01270880

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

A Phase II Trial of STA-9090 in Patients With Metastatic Castration-Resistant Prostate Cancer (CRPC) Pretreated With Docetaxel Based Chemotherapy

Sponsor: Barbara Ann Karmanos Cancer Institute

Conditions Adenocarcinoma of the Prostate Hormone-resistant Prostate Cancer Recurrent Prostate Cancer Stage IV Prostate Cancer
Interventions Hsp90 inhibitor STA-9090 RNA analysis enzyme-linked immunosorbent assay gene expression analysis laboratory biomarker analysis polymerase chain reaction reverse transcriptase-polymerase chain reaction spectrophotometry
Updated 8 times since 2017 Last updated: Aug 19, 2018 Started: Jan 31, 2011 Primary completion: Jul 31, 2014 Completion: Jul 31, 2014
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01270880, this PHASE2 trial focuses on Adenocarcinoma of the Prostate and Hormone-resistant Prostate Cancer and remains completed. Sponsored by Barbara Ann Karmanos Cancer Institute, it has been updated 8 times since 2011, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotCompleted~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshotCompleted~Oct 2018 – ~Jan 2021 · 27 months · monthly snapshotCompleted~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshotCompleted~Dec 2021 – ~Jul 2024 · 31 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 23 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  5. Oct 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Jun 2018 — Oct 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Jan 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Barbara Ann Karmanos Cancer Institute
  • National Cancer Institute (NCI)
Data source: Barbara Ann Karmanos Cancer Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations